ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit

BOSTON, March 31, 2016 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2^nd Annual Immuno-Oncology Summit on Thursday, April 7^th, 2016 at 9:35 a.m. ET. The conference is being held at the Boston Harbor Hotel in Boston, MA.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System^® technology, a switch to turn on and off, and precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Contact:

Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
[email protected]

David Pitts
Argot Partners
212-600-1902
[email protected]